CN104926941A - 牛源性抗金黄色葡萄球菌基因工程单链抗体、制备方法及其用途 - Google Patents
牛源性抗金黄色葡萄球菌基因工程单链抗体、制备方法及其用途 Download PDFInfo
- Publication number
- CN104926941A CN104926941A CN201510362092.2A CN201510362092A CN104926941A CN 104926941 A CN104926941 A CN 104926941A CN 201510362092 A CN201510362092 A CN 201510362092A CN 104926941 A CN104926941 A CN 104926941A
- Authority
- CN
- China
- Prior art keywords
- antibody
- chain antibody
- staphylococcus aureus
- gene
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000941 anti-staphylcoccal effect Effects 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 241000283690 Bos taurus Species 0.000 title abstract description 16
- 238000010353 genetic engineering Methods 0.000 title abstract description 6
- 241000191967 Staphylococcus aureus Species 0.000 claims abstract description 23
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims abstract description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 27
- 241000894006 Bacteria Species 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 9
- 238000002965 ELISA Methods 0.000 claims description 7
- 239000000427 antigen Substances 0.000 claims description 7
- 108091007433 antigens Proteins 0.000 claims description 7
- 102000036639 antigens Human genes 0.000 claims description 7
- 210000004027 cell Anatomy 0.000 claims description 7
- 239000013612 plasmid Substances 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 238000012216 screening Methods 0.000 claims description 5
- 230000006698 induction Effects 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 238000010276 construction Methods 0.000 claims description 2
- 238000012215 gene cloning Methods 0.000 claims description 2
- 230000000968 intestinal effect Effects 0.000 claims description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 2
- 230000006798 recombination Effects 0.000 claims description 2
- 238000005215 recombination Methods 0.000 claims description 2
- 238000003757 reverse transcription PCR Methods 0.000 claims description 2
- 238000012360 testing method Methods 0.000 abstract description 6
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 4
- 238000000338 in vitro Methods 0.000 abstract description 4
- 208000031462 Bovine Mastitis Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000013642 negative control Substances 0.000 description 10
- 210000005075 mammary gland Anatomy 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 239000013641 positive control Substances 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 230000003321 amplification Effects 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000005611 electricity Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 238000005267 amalgamation Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 238000009739 binding Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000001408 fungistatic effect Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 102000057593 human F8 Human genes 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 229940051173 recombinant immunotoxin Drugs 0.000 description 1
- 229940047431 recombinate Drugs 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000012882 sequential analysis Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000010421 standard material Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510362092.2A CN104926941B (zh) | 2015-06-26 | 2015-06-26 | 牛源性抗金黄色葡萄球菌基因工程单链抗体、制备方法及其用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510362092.2A CN104926941B (zh) | 2015-06-26 | 2015-06-26 | 牛源性抗金黄色葡萄球菌基因工程单链抗体、制备方法及其用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104926941A true CN104926941A (zh) | 2015-09-23 |
CN104926941B CN104926941B (zh) | 2018-10-19 |
Family
ID=54114383
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510362092.2A Active CN104926941B (zh) | 2015-06-26 | 2015-06-26 | 牛源性抗金黄色葡萄球菌基因工程单链抗体、制备方法及其用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104926941B (zh) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106243219A (zh) * | 2016-08-04 | 2016-12-21 | 上海交通大学 | 一种猪源性抗猪流行性腹泻病毒的单链抗体及其制备方法 |
CN106397585A (zh) * | 2016-07-29 | 2017-02-15 | 上海交通大学 | 一种牛源抗金黄色葡萄球菌的真核表达单链抗体、制备方法及其用途 |
CN108250295A (zh) * | 2018-01-16 | 2018-07-06 | 福州大学 | 一种利用噬菌体抗体库筛选雌激素受体α单链抗体的方法 |
CN109021109A (zh) * | 2018-07-20 | 2018-12-18 | 上海交通大学 | 一种牛源性抗金黄色葡萄球菌融合抗体scFv-Fc及其制备方法 |
CN111333724A (zh) * | 2018-12-19 | 2020-06-26 | 中国人民解放军军事科学院军事医学研究院 | 一种抗金黄色葡萄球菌肠毒素b的单克隆抗体yg11-1及其应用 |
CN111848790A (zh) * | 2020-08-07 | 2020-10-30 | 上海交通大学 | 一种牛源抗金黄色葡萄球菌的单链抗体及其制备和应用 |
CN113493510A (zh) * | 2021-07-07 | 2021-10-12 | 上海交通大学 | 一种牛源抗金黄色葡萄球菌LukD毒力因子的单链抗体及其制备和应用 |
CN114181306A (zh) * | 2021-12-31 | 2022-03-15 | 上海交通大学 | 一种牛源抗金黄色葡萄球菌毒力因子Hlb的单链抗体、制备方法和用途 |
CN114409778A (zh) * | 2021-12-31 | 2022-04-29 | 上海交通大学 | 一种牛源抑制金黄色葡萄球菌溶血功能的单链抗体及其制备方法和用途 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102863528A (zh) * | 2012-10-24 | 2013-01-09 | 上海交通大学 | 牛源性抗金黄色葡萄球菌单链抗体及其制备方法和应用 |
-
2015
- 2015-06-26 CN CN201510362092.2A patent/CN104926941B/zh active Active
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106397585A (zh) * | 2016-07-29 | 2017-02-15 | 上海交通大学 | 一种牛源抗金黄色葡萄球菌的真核表达单链抗体、制备方法及其用途 |
CN106243219A (zh) * | 2016-08-04 | 2016-12-21 | 上海交通大学 | 一种猪源性抗猪流行性腹泻病毒的单链抗体及其制备方法 |
CN106243219B (zh) * | 2016-08-04 | 2019-12-03 | 上海交通大学 | 一种猪源性抗猪流行性腹泻病毒的单链抗体及其制备方法 |
CN108250295A (zh) * | 2018-01-16 | 2018-07-06 | 福州大学 | 一种利用噬菌体抗体库筛选雌激素受体α单链抗体的方法 |
CN109021109A (zh) * | 2018-07-20 | 2018-12-18 | 上海交通大学 | 一种牛源性抗金黄色葡萄球菌融合抗体scFv-Fc及其制备方法 |
CN111333724A (zh) * | 2018-12-19 | 2020-06-26 | 中国人民解放军军事科学院军事医学研究院 | 一种抗金黄色葡萄球菌肠毒素b的单克隆抗体yg11-1及其应用 |
CN111848790A (zh) * | 2020-08-07 | 2020-10-30 | 上海交通大学 | 一种牛源抗金黄色葡萄球菌的单链抗体及其制备和应用 |
CN113493510A (zh) * | 2021-07-07 | 2021-10-12 | 上海交通大学 | 一种牛源抗金黄色葡萄球菌LukD毒力因子的单链抗体及其制备和应用 |
CN114181306A (zh) * | 2021-12-31 | 2022-03-15 | 上海交通大学 | 一种牛源抗金黄色葡萄球菌毒力因子Hlb的单链抗体、制备方法和用途 |
CN114409778A (zh) * | 2021-12-31 | 2022-04-29 | 上海交通大学 | 一种牛源抑制金黄色葡萄球菌溶血功能的单链抗体及其制备方法和用途 |
Also Published As
Publication number | Publication date |
---|---|
CN104926941B (zh) | 2018-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104926941A (zh) | 牛源性抗金黄色葡萄球菌基因工程单链抗体、制备方法及其用途 | |
CN106243219B (zh) | 一种猪源性抗猪流行性腹泻病毒的单链抗体及其制备方法 | |
CN103570831B (zh) | 牛源性抗金黄色葡萄球菌单链抗体及其制备方法和应用 | |
HRP20181085T1 (hr) | Protutijela koja vežu il-4 i/ili il-13 i njihova uporaba | |
JP2012100677A5 (zh) | ||
CN109021109A (zh) | 一种牛源性抗金黄色葡萄球菌融合抗体scFv-Fc及其制备方法 | |
CN113493510A (zh) | 一种牛源抗金黄色葡萄球菌LukD毒力因子的单链抗体及其制备和应用 | |
CN111848790B (zh) | 一种牛源抗金黄色葡萄球菌的单链抗体及其制备和应用 | |
CN106397585A (zh) | 一种牛源抗金黄色葡萄球菌的真核表达单链抗体、制备方法及其用途 | |
CN103497253A (zh) | 一种针对h2a.z变体的纳米抗体、其编码序列及应用 | |
Cunliffe et al. | Hitting the target but missing the point: recent progress towards adenovirus-based precision virotherapies | |
Hajeri et al. | Oncolytic adenoviruses: strategies for improved targeting and specificity | |
CN106008710B (zh) | 一种猪源性抗产肠毒素大肠杆菌K88 FaeG蛋白的单链抗体及其制备方法 | |
CN104804092B (zh) | 一种抗b细胞生长刺激因子的纳米抗体及其用途 | |
CN101550191B (zh) | 一种恶性黑素瘤t细胞纳米抗体、其编码序列及应用 | |
CN106928363A (zh) | 一种FAP纳米抗体Nb12 | |
CN102786596A (zh) | 一种抗p21Ras蛋白的单链抗体KGH-R1-ScFv及其应用 | |
CN107417792A (zh) | 抗cd40‑her2双特异性单链抗体及其在制备抗肿瘤药物中的应用 | |
Karuppanan et al. | Expression, purification, and biophysical characterization of a secreted anthrax decoy fusion protein in Nicotiana benthamiana | |
CN104804090B (zh) | 一种抗b细胞生长刺激因子的纳米抗体和用途 | |
CN105198992B (zh) | 一种人源抗创伤弧菌溶血素蛋白(vvh)抗体的制备方法与应用 | |
CN106536738A (zh) | 抗体基因的表达‑分泌系统 | |
US20140350225A1 (en) | Anti-bfgf humanized double-stranded antibody with stable disulfide bond, preparation method and application thereof | |
CN107880127B (zh) | 全人源抗pdl-1单链抗体b129及其应用 | |
CN103088033A (zh) | 抗拟除虫菊酯类农药scFv的抗体基因及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20220321 Address after: 750004 East Zone, floor 1, building 1, Ningxia high tech entrepreneurship service center, Ning'an West Lane, Xilu Road, high tech Development Zone, Jinfeng District, Yinchuan City, Ningxia Hui Autonomous Region Patentee after: Antibenda (Ningxia) Biotechnology Co.,Ltd. Address before: 200240 No. 800, Dongchuan Road, Shanghai, Minhang District Patentee before: SHANGHAI JIAO TONG University |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240115 Address after: Building A8, East Zone, Jinrong Science and Technology Park, No. 158 Ji'an South Road, High tech Industrial Development Zone, Yangzhou City, Jiangsu Province, 225100 Patentee after: Antibokang (Yangzhou) Biotechnology Co.,Ltd. Patentee after: Shanghai Ancunzhi Biotechnology Co.,Ltd. Address before: 750004 East Area, 1st Floor, Building 1, Ningxia High tech Entrepreneurship Service Center, Ning'an West Lane, Xiliu Road, Jinfeng District, Yinchuan City, Ningxia Hui Autonomous Region Patentee before: Antibenda (Ningxia) Biotechnology Co.,Ltd. |
|
TR01 | Transfer of patent right |